| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11.23 | Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia | 270 | GlobeNewswire (Europe) | LDL-C Reductions Up to 55% and Blood PCSK9 Protein Reductions Up to 84% Observed After a Single Infusion of VERVE-101 at Potentially Therapeutic Doses Safety Profile Supports Continued Development... ► Artikel lesen | |
| 12.11.23 | Lexicon Pharmaceuticals, Inc.: INPEFA (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data | 300 | GlobeNewswire (Europe) | Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and separately... ► Artikel lesen | |
| 12.11.23 | 89bio, Inc.: 89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting 2023 | 177 | GlobeNewswire (Europe) | -Reductions in key non-invasive tests (NITs) of liver inflammation and fibrosis support previously demonstrated fibrosis improvements across compensated cirrhotic (F4) patients at week 24- -A responder... ► Artikel lesen | |
| 12.11.23 | Amarin Corporation plc: New REDUCE-IT Analyses Show VASCEPA (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline | 318 | GlobeNewswire (Europe) | -- Analysis Also Found IPE Was Associated with a 41% Reduction in Total Events Compared with Placebo -- -- Subgroup Almost Exclusively Comprised of Patients with Established Cardiovascular Disease... ► Artikel lesen | |
| 12.11.23 | Alfen N.V.: Alfen delivers record-quarter in revenues and improves EBITDA compared to Q2 2023 | 1.162 | GlobeNewswire (Europe) | Highlights:
• Q3 2023 revenues amounted to €136.4m, a growth of 11% versus Q3 2022 (€123.2m).
• Gross margin at 29.4% compared with 34.8% in Q3 2022 and 28.8% in Q2 2023.
• Adjusted EBITDA of €17.3m... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 420 |
| BAYER | 269 |
| BYD | 239 |
| NVIDIA | 226 |
| NEL | 221 |
| PLUG POWER | 197 |
| TESLA | 190 |
| TUI | 187 |
| SUPER MICRO COMPUTER | 186 |
| DEUTSCHE BANK | 180 |
| APPLE | 178 |
| RHEINMETALL | 159 |
| AMAZON | 145 |
| RWE | 145 |
| DEUTSCHE LUFTHANSA | 142 |
| MERCEDES-BENZ | 139 |
| BERKSHIRE HATHAWAY | 125 |
| COMMERZBANK | 116 |
| BIONTECH | 114 |
| PAYPAL | 114 |
| ALLIANZ | 111 |
| BASF | 110 |
| RENK GROUP | 109 |
| AIXTRON SE | 108 |
| VOLKSWAGEN | 107 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
